To gain understanding as to why lethal drugs pass FDA review, read the front page article in The Wall Street Journal (below) describing the transformation of the FDA from watchdog to lapdog. Continue reading →
“More than a year after the Food and Drug Administration announced it had strengthened its drug safety system, the agency still lacks a reliable system for keeping track of emerging problems, congressional investigators concluded in a report to be released today.” [Los Angeles Times, below]
"Are we becoming patients for profit? That is the question knowledgeable observers are asking. Continue reading →
The Center for Public Integrity reports that FDA officials circumvent the prohibition on accepting trips from drug and medical device manufacturers. Continue reading →
"Every year, drug companies spend $14 billion to test experimental substances on humans. Across the U.S., the centers that do the testing–and the regulators who watch them–allow scores of human test subjects to be injured or killed."
Thank you for the opportunity to submit this testimony for the record.
My name is Meryl Nass, M.D., and I have worked for the past twenty years as an emergency physician and internist in community hospitals in the northeastern US. I have also studied many aspects of bioterrorism since 1989. I am the person who first demonstrated, in 1992, that one could investigate an epidemic retrospectively, and prove that it was due to biological warfare, using Rhodesia’s 1978-80 anthrax epidemic as a model.
Presented by Vera Hassner Sharav
14th Tri-Service Clinical Investigation Symposium
Sponsored by The U.S. Army Medical Department and The Henry M. Jackson Foundation for the Advancment of Military Medicine
The cornerstone of public trust in medical research is the integrity of academic institutions and the expectation that universities, which rely on public funding, have a responsibility to serve the public good. Financial conflicts of interest affect millions of American people – those who are subjects of clinical trials testing new drugs and those who are prescribed drugs after their approval. Continue reading →
CONFLICTS OF INTEREST Presented by Vera Hassner Sharav 14th TRI-SERVICE CLINICAL INVESTIGATION SYMPOSIUM Sponsored By THE U.S. ARMY MEDICAL DEPARTMENT And THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCMENT OF MILITARY MEDICINE May 5-7, 2002 The cornerstone of public trust in medical . . . Continue reading →
AHRP InfoMail Return to Home Page Return to InfoMail Media Coverage List MediaCoverage News Stories on Human ResearchProtection andCommentary by Vera Hassner Sharav March 8, 2002 FDA and Pharmaceutical Industry inPrivate Deal to Speed Drug Approval Process FYI According to the Washington . . . Continue reading →
AHRP InfoMail Return to Home Page Return to InfoMail Media Coverage List MediaCoverage News Stories on Human ResearchProtection andCommentary by Vera Hassner Sharav February 19, 2002 How a New FDA Policy Led toSeven Deadly Drugs FYI The Seattle Times reports, "Therelationship between the . . . Continue reading →